Eli Lilly and Co's EBIT per Share for the
three
months ended in Mar. 2026 was CHF8.59.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF31.76.
During the past 12 months, the average EBIT per Share Growth Rate of Eli Lilly and Co was 74.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 53.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 33.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 23.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Eli Lilly and Co's EBIT per Share or its related term are showing as below:
XSWX:LLY'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -25.9 Med: 11.6 Max: 53.4
Current: 53.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Eli Lilly and Co was 53.40% per year. The lowest was -25.90% per year. And the median was 11.60% per year.
XSWX:LLY's 3-Year EBIT Growth Rate is ranked better than 89.98% of 808
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs XSWX:LLY: 53.40
Eli Lilly and Co's EBIT for the
three
months ended in Mar. 2026 was CHF7,698 Mil.
Eli Lilly and Co (XSWX:LLY) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Eli Lilly and Co EBIT per Share Related Terms
Eli Lilly and Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF31.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (XSWX:LLY) has a EBIT per Share of CHF31.76 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Eli Lilly and Co and its competitors. According to the industry distribution chart, Eli Lilly and Co ranks #81 out of 808 companies in the Drug Manufacturers industry, placing it in the top 10%.
Is Eli Lilly and Co's EBIT per Share too high?
Eli Lilly and Co's current EBIT per Share is CHF31.76. Based on the distribution chart, Eli Lilly and Co ranks #81 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's EBIT per Share compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #81 out of 808 companies for EBIT per Share. This places Eli Lilly and Co in the top 10% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current EBIT per Share is CHF31.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,114.27, compared to a current price of CHF955.00 — trading 14.3% below its estimated fair value. The current EBIT per Share is CHF31.76. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current EBIT per Share is CHF31.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF955.00 is trading 14.3% below its estimated GF Value™ of CHF1,114.27.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
EBIT per Share: CHF31.76
GF Value™: CHF1,114.27 vs. price of CHF955.00 (14.3% below fair value)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score
Get the complete analysis for XSWX:LLY
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
